Russia Biosurgery Market Overview, 2031

Key Insights

• The Russia biosurgery market represents a significant and evolving national market for surgical biomaterials within Eastern Europe. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.
• The Russia biosurgery market is distinguished by its large-scale healthcare system, substantial surgical volumes, and ongoing regulatory modernization. According to Rosstat data, total surgical interventions in Russian inpatient settings reached 10,383,500 procedures in 2024, reflecting the immense scale of surgical activity. Healthcare expenditure in Russia stood at 7.58% of GDP in 2025, with health spending per capita at approximately $3,204 PPP. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the rapid expansion of high-tech medical care and increasing localization of medical device manufacturing.
• Russia's healthcare system performed 10,383,500 surgical interventions in inpatient settings in 2024, reflecting the country's substantial surgical volume and providing a robust foundation for biosurgical product demand. Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques and the expansion of high-tech surgical methods across Russian hospitals.
• Russia's aging population represents a significant long-term demand driver. By early 2025, 25.8 million people (17.7% of the population) were aged 65 years or older, up from 14.6 million in 1990. This proportion is projected to reach 24% by mid-century. The regulatory environment is undergoing significant modernization. From March 1, 2025, new medical device registration rules came into effect, reducing registration time for domestic devices to 10 days (from 50 days previously) and implementing a "one-stop-shop" digital system through Gosuslugi.

Market Outlook
• According to the research report, " Russia Biosurgery Market Overview, 2031," published by Bonafide Research, the Russia Biosurgery market is anticipated to grow at more than 5.49% CAGR from 2026 to 2031. The Russian biosurgery market is expected to maintain steady growth through 2031, supported by demographic trends, ongoing regulatory modernization, and expanding surgical volumes across both public hospitals and private healthcare facilities. The market's growth trajectory is intrinsically linked to the broader Russian healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.
• Russia's healthcare expenditure continues to rise, reaching 7.58% of GDP in 2025. Health spending per capita stands at approximately $3,204 PPP. High-tech medical care (VMP) financing in 2025 is projected to reach 30% of total inpatient care funding (0.49 trillion rubles out of 1.64 trillion rubles).
• The aging Russian population represents the most significant long-term demand driver. With 25.8 million people aged 65 and over (17.7% of the population) and projections indicating that one in four Russians will be over 65 by mid-century, the incidence of age-related conditions requiring surgical intervention will increase correspondingly. Over 4 million patients in Russia suffer from osteoarthritis of major joints. Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. The number of high-tech medical care (VMP) methods reached nearly 1,700 types in 2025, with the greatest growth observed in neurosurgical operations (2.6-fold increase) and cardiac surgery (1.8-fold increase).
• Rising surgical procedures are a key driver propelling market expansion. Total inpatient surgical interventions increased from 9.88 million in 2015 to 10.38 million in 2024, with high-tech surgical procedures nearly doubling from 741,000 in 2014 to 1.349 million in 2024. The share of high-tech operations relative to total surgeries increased from 8.1% in 2015 to 12.8% in 2024.



Market Dynamics

Driver: High and Growing Surgical Volumes and High-Tech Expansion
Russia performs over 10 million surgical procedures annually in inpatient settings, with total surgical interventions reaching 10,383,500 procedures in 2024. The expansion of high-tech medical care has been particularly significant: the number of high-tech surgical procedures nearly doubled from 741,000 in 2014 to 1,349,700 in 2024. The most substantial growth occurred in neurosurgical operations (2.6-fold increase), procedures on male reproductive organs (2.6-fold), ENT surgeries (2.0-fold), cardiac surgeries (1.8-fold), and breast surgeries (1.8-fold). Coronary angioplasty procedures increased from 127,600 in 2014 to 335,600 in 2024. The share of high-tech operations relative to total surgeries increased from 8.1% in 2015 to 12.8% in 2024. Healthcare expenditure of 7.58% of GDP provides the financial infrastructure to support expanding surgical volumes, with high-tech care financing reaching 30% of total inpatient funding.

Challenge: Healthcare Spending Constraints and Import Substitution Pressures
Despite significant healthcare investment, Russia faces persistent challenges that affect the biosurgery market. Healthcare spending as a percentage of GDP stands at 7.58%, with some sources indicating that public health spending remains at approximately 3.4–3.5% of GDP. Health spending per capita of approximately $3,204 PPP is below many Western European counterparts. Sanctions and geopolitical tensions have accelerated import substitution policies, with Roszdravnadzor reporting 90% import substitution for small medical devices and consumables. The share of domestically acquired ventilators in the state healthcare system exceeded 80% in 2025. While this creates opportunities for domestic manufacturers, it also creates regulatory and supply chain challenges for international biosurgery companies seeking to maintain market access. Additionally, the healthcare system faces capacity constraints, with the number of high-tech operations representing only 12.8% of total surgical procedures.



Trend: Accelerating Regulatory Modernization and Localization of Medical Device Manufacturing
The Russian biosurgery market is experiencing a significant transformation driven by regulatory modernization and localization of medical device manufacturing. On March 1, 2025, new medical device registration rules came into effect, fundamentally modernizing the market access process. Key changes include: 10-day registration for domestic devices (compared to 50 days previously), full "one-stop-shop" support from documentation development to dossier review, and mandatory electronic document submission through Gosuslugi. In 2025, Roszdravnadzor registered 3,400 medical device names, with approximately 40% developed and produced in Russia. The number of registered Russian medical devices increased by 10% in 2025, with high-tech medical device registrations growing by 20%. Registered devices include robotic surgical systems, joint components, implants, orthopedic constructs, surgical staplers, and endoscopic instruments. The regulatory system is now "focused on maximum support for Russian manufacturers and digitalization of processes", creating new opportunities for both domestic and foreign manufacturers who localize production.

Policies

• The Eurasian Economic Union (EAEU) medical device regulations serve as the core regulatory framework for biosurgical products in Russia. The EAEU rules for registration and safety, quality, and efficacy expertise of medical devices were updated by Council Decision No. 50 of July 8, 2025. Classification rules were amended by Collegium Decision No. 18 of February 18, 2025.
• Roszdravnadzor (Federal Service for Surveillance in Healthcare) serves as the competent authority for medical devices in Russia, overseeing registration, market surveillance, and post-market monitoring. In 2025, Roszdravnadzor registered 3,400 medical device names.
• New medical device registration rules came into effect on March 1, 2025, reducing registration time for domestic devices to 10 days (from 50 days previously) and implementing a "one-stop-shop" digital system through Gosuslugi.
• The government's import substitution policy has significantly accelerated localization of medical device manufacturing. Roszdravnadzor reported 90% import substitution for small medical devices and consumables, with domestically acquired ventilators exceeding 80% of state healthcare procurement in 2025.
• The expansion of high-tech medical care (VMP) continues to be a government priority. The number of VMP methods reached nearly 1,700 in 2025, with VMP financing projected to reach 30% of total inpatient care funding in 2025.
• Medical device registration requirements have been modernized with a focus on digitalization. Applications and documents are now submitted exclusively through Gosuslugi, with full electronic document workflow. The system is designed to provide "maximum support for Russian manufacturers".

Segment Analysis

Russia Biosurgery Market By Product
• Bone-Graft Substitutes represent the largest product category within the Russian biosurgery market, driven by the high volume of orthopedic and trauma procedures. The annual demand for knee arthroplasty in Russia is estimated at approximately 300,000 procedures, reflecting the significant burden of osteoarthritis affecting over 4 million patients. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging Russian population with 17.7% aged 65 and over continues to drive demand for musculoskeletal interventions.
• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. Russian domestic manufacturers are developing innovative hemostatic materials, including Damrex developed at Sechenov University and V-gemostopan developed by research institutes.
• Surgical Sealants and Adhesives represent the fastest-growing product category in the Russian biosurgery market, driven by increasing adoption of minimally invasive and high-tech surgical techniques. Russian researchers have developed surgical glue prototypes based on animal proteins for use in cardio- and neurosurgical operations. Domestic manufacturers such as PLASMA-FTK LLC produce Cryophyt surgical sterile glue.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in Russian hospitals.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines. BEIEN-SURG staplers and cartridges for laparoscopic and open surgeries are supplied in Russia, with surgical staplers and endoscopic instruments among the devices registered in 2025.

Russia Biosurgery Market By Application
• Orthopedic Surgery is the largest application area for biosurgical products in Russia, driven by the high volume of joint replacement, trauma, and spinal procedures. Over 4 million patients in Russia suffer from osteoarthritis of major joints, with annual demand for knee arthroplasty estimated at 300,000 procedures. The Russian Ilizarov Scientific Center for Restorative Traumatology and Orthopaedics continues to advance orthopedic surgical techniques.
• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. Total surgical interventions reached 10,383,500 procedures in 2024.
• Cardiovascular Surgery represents the fastest-growing application area in the Russian biosurgery market, driven by the high prevalence of cardiovascular disease and significant expansion of cardiac surgical capacity. Coronary angioplasty procedures increased from 127,600 in 2014 to 335,600 in 2024. Cardiac surgeries increased 1.8-fold over 10 years, reflecting sustained growth in this specialty.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks. Neurosurgical operations increased 2.6-fold over 10 years, making it one of the fastest-growing surgical specialties in Russia and driving demand for specialized biosurgical products.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues. Breast surgeries increased 1.8-fold, while plastic surgery procedures exceeded 38,000 operations in 2025, including approximately 16,000 interventions on the head and neck.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, and tissue repair.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system. Procedures on male reproductive organs increased 2.6-fold over 10 years, reflecting growing demand in this specialty.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions. ENT surgeries increased 2.0-fold over 10 years.

Russia Biosurgery Market By Source/Origin
• Biologic products represent the largest source category in the Russian biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. Russian manufacturers are developing innovative biologic hemostatic materials, including Damrex and V-gemostopan.
• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Russian market, driven by cost-effectiveness, consistent quality, and localization of manufacturing. Russian researchers have developed synthetic surgical glue prototypes and domestic manufacturers such as PLASMA-FTK LLC produce synthetic sealants. The government's import substitution policy and regulatory support for domestic manufacturers are accelerating synthetic product development.

Russia Biosurgery Market By End-User
• Hospitals remain the largest end-user segment for biosurgical products in Russia, accounting for the majority of revenue. Total inpatient surgical interventions reached 10,383,500 procedures in 2024. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization. High-tech medical care is predominantly delivered in hospital settings.
• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Russian biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity supports the adoption of biosurgical products in these settings.
• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Russia Biosurgery Procedure Economics

• Biosurgery testing in Russia operates within a dual economic structure, encompassing a vast, subsidised public network and an increasingly commercialised private sector.
• State Laboratories (Rosselkhoznadzor Network): The public laboratory network includes federal reference centres (FGBU "VGNKI", FGBU "VNIIZZH"), interregional (zonal), and district-level laboratories. These are typically government-funded and provide a baseline of diagnostic services at low cost. They are tasked with official surveillance, disease control, and export certification. These labs are often considered a competitor to the private sector.
• Private Commercial Laboratories: The commercial market consists of independent diagnostic networks and the in-house labs of large agricultural holdings. Independent labs like NITs "Cherkizovo", Vet.INVITRO, and Shans Bio operate on a fee-for-service basis. In-house labs, such as those run by "Miraktor" and "Rusagro", are funded by their parent companies and, while mainly serving internal needs, may also offer services to external clients.
• Pricing and Accreditation: Pricing in the private sector is market-driven and often reflects the speed, reliability, and accreditation of the laboratory. While state labs may be cheaper, private labs are increasingly considered for their responsiveness. An important economic factor is the drive for accreditation to ISO 17025; accredited laboratories can command a premium for their services, as their results are accepted for international trade and can prevent costly duplicate testing.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others"